CClinicalTrials.gg
RecruitingNCT07008170LERVUpdated Jun 19, 2025

Laparoendoscopic Rendezvous for Concomitant Gall Bladder Stones and Common Bile Duct Stones

An interventional study of Laparoendoscopic rendezvous in Gall Stone, Common Bile Duct Calculi and Cholecystitis, Chronic, sponsored by Minia University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by Minia University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Chronic calculous cholecystitis in pediatric patients leads to choledocholithiasis in about 12% of cases. These patients require removal of stones from the common bile duct. The most common method of cleaning the common bile duct is endoscopic retrograde cholangiopancreatography, and the standard technique for removing the gallbladder is laparoscopic cholecystectomy. There are different approaches to the treatment of this category of patients: laparoscopic common bile duct exploration (LCBDE), laparoendoscopic rendezvous method (LERV) and one-stage LC( laparoscopic cholecystectomy) after ERCP( endoscopic retrograde cholangiopancreatography).

The aim of this prospective study is to evaluate the efficacy and safety Laparoendoscopic rendezvous for difficult cholecystocholedocholithiasis.

Read the detailed description

The incidence of concomitant choledocholithiasis in patients with gallstone disease has been reported to range between 10% and 20% depending on geographic distribution.The ideal management of cholecysto-choledocholithiasis is still a matter of debate; different modalities, including the open and the laparoscopic approach, and sequential or simultaneous techniques, have been applied with success.

The management of gallbladder stones (lithiasis) concomitant with bile duct stones is controversial. The management of CBD( common bile duct) stones has evolved considerably since the advent of laparoscopic surgery. The more frequent approach is a two-stage procedure, with endoscopic sphincterotomy and stone removal from the bile duct followed by laparoscopic cholecystectomy. The laparoscopic-endoscopic rendezvous combines the two techniques in a single-stage operation. So the aim of this study was to evaluate one-stage LC with intra-operative endoscopic sphincterotomy (IOES) vs two-stage pre-operative endoscopic sphincterotomy (POES) followed by LC for the treatment of cholecystocholedocholithiasis Endoscopic Retrograde Cholangiopancreatography (ERCP) is one of the most technically challenging procedures in gastrointestinal endoscopy. Selective deep cannulation is a critical step for the performance of ERCP. The incidence of difficult cannulation has been reported in many studies, ranging from 10% to 40% in patients with native papilla. Difficult cannulation is an independent risk factor for post-ERCP pancreatitis (PEP).

The definition of difficult cannulation has been proposed by European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Initial cannulation is considered difficult with the presence of one or more of the following: more than 5 min for attempting to cannulate; more than 5 contacts with the papilla; more than 1 unintended pancreatic duct cannulation or opacification.

Aim of the study is to evaluate use of laparoendoscopic rendezvous for difficult cholecystocholedocholithiasis using preprocedural abdominal CT findings. Primary outcome is to performs difficult biliary cannulation by rendezvous technique while secondary outcomes is to to detect morbidity (especially post-ERCP pancreatitis) , success of CBD clearance and to detect overall hospital

Risk factors of difficult cannulation during ERCP based on preprocedural abdominal CT findings in the study :

  1. periampullary diverticulum
  2. Location of the major papilla other than the descending duodenum
  3. Presence of papilla bulging
  4. Choledochoduodenal (CD) angle: the angle between the distal common bile duct and adjacent duodenum,
  5. CBD( common bile duct) diameter
  6. Far distal CBD (common bile duct) stone B. Laboratory investigation: normal bilirubin C. Previous upper gastrointestinal tract surgery/ Surgically altered anatomy
02

Conditions studied

  • Gall Stone
  • Common Bile Duct Calculi
  • Cholecystitis, Chronic
  • Choledocholithiasis
  • Periampullary Diverticula
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients having stone(s) in the gallbladder and concurrent common bile duct , as determined by MRCP(magnetic resonance cholangiopancreatography) or US.
  • Patients with acute cholecystitis, acute cholangitis, obstructive jaundice, and those with highly suspicious criteria for common bile duct stones, such as dilated CBD( common bile duct ) on US examination > 7 mm in diameter without obvious common bile duct stones, high serum bilirubin level, and/or high serum alkaline phosphatase level, were also included in this study. (high risk for cholecystocholedocholithiasis)
  • Previous failed ERCP attempt
  • Patients fit for general anesthesia and tolerant of pneumoperitoneum and endoscopic procedures.

Exclusion criteria

Exclusion Criteria:

  • History of hepatobiliary surgery as choledochoduodenal anastomosis
  • A Previous upper abdominal surgery as total or partial gastric resection.
  • Morbid obesity.
  • Uncorrectable coagulopathy.
  • Patients who refused to give consent.
  • Pregnancy.
  • Suspected malignant biliary stricture or cholangiocarcinoma
  • Severe acute cholangitis with hemodynamic instability or septic shock requiring immediate biliary drainage (may necessitate emergent ERCP or percutaneous drainage first)
  • Impacted CBD stones or stones deemed too large for endoscopic extraction (e.g., > 1.5 cm)
  • Severe cardiopulmonary disease significantly increasing operative risk.
  • Intrahepatic bile duct stones with indications for surgery.
  • Patients with choledocholithiasis >2 cm or a large number of stones were difficult to remove.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Other
    Laparoendoscopic rendezvous(LERV)

    Step 1: Laparoscopic Phase Step 2: Endoscopic Phase Step 3: Completion

    Procedure: Laparoendoscopic rendezvous

Interventions

  • ProcedureLaparoendoscopic rendezvous

    The main principles of LERV technique consists of 1. An antegrade trans cystic cannulation of the bile duct during laparoscopic cholecystectomy, with a guidewire that can be retrieved with a duodenoscope, thus facilitating retrograde bile duct cannulation. 2. An over-the-wire sphincterotome is then inserted and standard maneuvers of endoscopic common bile duct stones clearance are performed. 3. The procedure is then completed by cholecystectomy in one procedure

05

What researchers measure

Primary outcomes

  1. Assess the success rate of LERV for difficult cannulation

    Assess the success rate of LERV for difficult cannulation

    Time frame: Intraoperative

Secondary outcomes

  1. assess the success rate of LERV in clearing the common bile duct in patients with choledocholithiasis

    CBD clearance success,Complete extraction of all stones during LERV judged by ERCP imaging

    Time frame: intraoperative

  2. incidence of postsphincterotomy bleeding

    obvious bleeding during ERCP Or delayed as melena

    Time frame: 30 days after LERV

  3. incidence of Acute pancreatitis

    increase serum amylase and lipase

    Time frame: 30 days after ERCP

  4. Recurrence of common bile duct stones

    The diagnosis of the stone in the common bile duct was made by MRI, CT scan and ultrasound.

    Time frame: 60 days after LERV

  5. Incidence of bile leak

    bile aspirated from the abdominal cavity

    Time frame: 30 days after LERV

  6. incidence of Perforation

    by CT, radiography (fluid or gas in the retroperitoneal space or abdominal cavity, visual picture during endoscopic examination)

    Time frame: 30 days after LERV

  7. incidence of Acute cholangitis

    intermittent chills, fever, increased proinflammatory blood markers after ERCP

    Time frame: 60 days after LERV

  8. incidence of bile duct stricture

    after LERV

    Time frame: 1 year after LERV

06

Study locations

1 of 1 sites recruiting
  • Liver and GIT hospital , Minia University
    Minya, 61519, Egypt
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07008170
Lead sponsor
Minia University
Responsible party
Saleh Khairy Saleh MD (Lecturer, Minia University) — Principal investigator
First posted
Jun 6, 2025
Start date
Jun 15, 2025
Primary completion
Jun 15, 2026 (estimated)
Completion
Jul 15, 2026 (estimated)
Last update
Jun 19, 2025

Study contacts

Saleh K Saleh, MD
Contact
salehkhairy@mu.edu.eg
01201765401 ext. +2
Ayman M Hassanen, MD
Contact
Ayman.hassan@mu.edu.eg
0 109 275 8555 ext. +2
Saleh K Saleh, MD
principal investigator · Minia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion